UCB SA (EBR: UCB)
Belgium
· Delayed Price · Currency is EUR
169.90
+5.55 (3.38%)
Nov 20, 2024, 5:39 PM CET
UCB SA Employees
As of December 31, 2023, UCB SA had 9,083 total employees, including 8,450 full-time and 633 part-time employees. The number of employees increased by 380 or 4.37% compared to the previous year.
Employees
9,083
Change (1Y)
380
Growth (1Y)
4.37%
Revenue / Employee
€606,000
Profits / Employee
€26,667
Market Cap
32.23B
Employees Chart
Employees History
UCB SA News
- 22 hours ago - Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside - Benzinga
- 22 hours ago - FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease - Benzinga
- 1 day ago - UCB gets FDA approval for Bimzelx for hidradenitis suppurativa - Seeking Alpha
- 1 day ago - Biogen, UCB release phase 3 data on lupus candidate dapirolizumab - Seeking Alpha
- 9 days ago - United Community Banks: Too Rich For My Blood - Seeking Alpha
- 5 weeks ago - Bimzelx Powers UCB To New Heights: Deep Dive Into The Company's Growth Strategy - Seeking Alpha
- 7 weeks ago - UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024 - Benzinga
- 2 months ago - UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024 - Benzinga